ClinicalThought

Share

Program Content

Activities

  • Rela/Nivo 1L Melanoma
    What to Know About the Novel Anti–LAG-3 Checkpoint Inhibitor Relatlimab in Melanoma
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 21, 2022

    Expires: March 20, 2023

Faculty

cover img faculity

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb